Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy -- Mayo Clinic

Table 1.

Surgical Techniques For Outflow Obstruction in Patients With Hypertrophic Cardiomyopathy

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Joseph A. Dearani, MD

Professor of Surgery, Mayo Clinic and Foundation, Rochester, Minnesota

Disclosures

Disclosure: Joseph A. Dearani, MD, has disclosed no relevant financial relationships.

Steve R. Ommen, MD

Associate Professor of Medicine, Mayo Clinic and Foundation, Rochester, Minnesota

Disclosures

Disclosure: Steve R. Ommen, MD, has disclosed no relevant financial relationships.

Bernard J. Gersh, MD

Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota

Disclosures

Disclosure: Bernard J. Gersh, MD, has disclosed no relevant financial relationships.

Hartzell V. Schaff, MD

Professor of Surgery and Chair, Mayo Clinic and Foundation, Rochester, Minnesota

Disclosures

Disclosure: Hartzell V. Schaff, MD, has disclosed no relevant financial relationships.

Gordon K. Danielson, MD

Emertius Professor of Surgery, Division of Cardiovascular Surgery, Mayo Clinic and Foundation, Rochester, Minnesota

Disclosures

Disclosure: Gordon K. Danielson, MD, has disclosed no relevant financial relationships.

processing....

Summary and Introduction

Summary

Septal myectomy has been the gold standard treatment for the relief left ventricular outflow tract obstruction and cardiac symptoms in both adults and children with obstructive hypertrophic cardiomyopathy. In almost all circumstances, abnormalities of the mitral valve and subvalvar mitral apparatus can be managed without the need for mitral valve replacement, and other cardiac lesions can be repaired simultaneously. In the current era, the operative mortality for isolated septal myectomy at an experienced center is low in both children and adults (approximately 1%). Excellent late results with myectomy are gratifying: 90% of patients improve by at least one NYHA class, and improvements persist in most individuals on late follow-up. Late survival in patients with obstructive hypertrophic cardiomyopathy who undergo myectomy exceeds that of patients who do not receive surgical treatment and, in addition, myectomy may be associated with reduced long-term risk of sudden cardiac death. These results should serve as a basis for comparison with newer nonsurgical treatment regimens.

Introduction

Transaortic septal myectomy is currently considered to be the most appropriate treatment for patients with obstructive hypertrophic cardiomyopathy (HCM) who have severe symptoms unresponsive to medical therapy.^[1-18] The learning curve for performing this procedure is considerable, however, and early surgical experience was associated with complications of complete heart block, ventricular septal defect, injury to the aortic or mitral valves, and incomplete relief of obstruction. In the few centers with a special interest in the management of HCM, the results of surgery have vastly improved. Drawing on the experience gained at our center, the Mayo Clinic, Rochester, MN, we present a review of septal myectomy in appropriate patients with obstructive HCM.

Page 1 of 9

History of Surgical Treatment

Summary and Introduction
History of Surgical Treatment
Indications for Operation
Surgical Technique
Septal Myectomy: Long-term Results
Recurrent LVOTO After Septal Myectomy
Septal Myectomy After Alcohol Septal Ablation
Conclusions
Key Points

Print
Like Tweet

Table 1.

Surgery Insight: Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy -- The Mayo Clinic Experience

Summary and Introduction

Summary

Introduction

Table of Contents

Table 1.

Faculty and Disclosures

Author(s)

Joseph A. Dearani, MD

Steve R. Ommen, MD

Bernard J. Gersh, MD

Hartzell V. Schaff, MD

Gordon K. Danielson, MD

Surgery Insight: Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy -- The Mayo Clinic Experience

Summary and Introduction

Summary

Introduction

Table of Contents